NYSEAMERICAN:NNVCNanoViricides Stock Price, Forecast & News

NanoViricides is scheduled to release its next quarterly earnings announcement on Friday, August 28th 2020. View our earnings forecast for NanoViricides.

NanoViricides Inc (NYSEAMERICAN:NNVC) issued its quarterly earnings data on Tuesday, February, 19th. The company reported ($0.68) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by $0.08. View NanoViricides' earnings history.

Shares of NanoViricides reverse split before market open on Tuesday, September 24th 2019. The 1-20 reverse split was announced on Thursday, September 12th 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 23rd 2019. An investor that had 100 shares of NanoViricides stock prior to the reverse split would have 5 shares after the split.

Headlines about NNVC stock have trended negative on Sunday, InfoTrie reports. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. NanoViricides earned a media sentiment score of -2.2 on InfoTrie's scale. They also gave media stories about the company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the company's share price in the next several days. View the latest news about NanoViricides.

NanoViricides saw a drop in short interest in the month of June. As of June 15th, there was short interest totaling 303,800 shares, a drop of 30.8% from the May 31st total of 438,900 shares. Based on an average daily volume of 997,600 shares, the short-interest ratio is currently 0.3 days. Currently, 3.9% of the shares of the company are sold short. View NanoViricides' Current Options Chain.

Some companies that are related to NanoViricides include Eco Animal Health Group (EAH), BEXIMCO PHARMAC/S GDR REGS (BXP), Allergy Therapeutics (AGY), Trilogy International Partners (TRL), Recce Pharmaceuticals (RCE), Futura Medical (FUM), Vita Life Sciences (VLS), Pharmaxis (PXS), Antisense Therapeutics (ANP), China Pharma (CPHI), Avivagen (VIV), Sareum (SAR), Patrys (PAB), Cathay International (CTI) and N4 Pharma (N4P). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other NanoViricides investors own include Cytosorbents (CTSO), Rekor Systems (REKR), Micron Technology (MU), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Domino's Pizza (DPZ), AbbVie (ABBV), Novavax (NVAX), Vaxart (VXRT) and NVIDIA (NVDA).

NanoViricides trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NNVC."

Shares of NNVC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NNVC stock can currently be purchased for approximately $7.25.

NanoViricides has a market capitalization of $65.78 million. NanoViricides employs 7 workers across the globe.

The official website for NanoViricides is www.nanoviricides.com.

NanoViricides' mailing address is 1 Controls Dr, SHELTON, CT 06484-6153, United States. The company can be reached via phone at +1-203-9376137.